Two Drugmakers Dominate Obesity Boom, Tiny Fund Holds Both
Two drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
A practical comparison of retirement index funds and target date funds, outlining when each may be the smarter pick for different retirement goals.
26,044 articlesTwo drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
Meta Platforms is considering cutting up to 20% of its workforce to fund AI infrastructure through 2028. The move mir...
Ark Invest disclosed a new Alphabet stake, triggering debate over Google’s growth drivers and the broader tech rally....
A single indicator could steer the next 12 months for the iShares 20+ Year Treasury Bond ETF (TLT). If the 30-year yi...
As investors scan headlines in June, Comcast's bold $8 billion UK theme park plan stands out. This article explains w...
Alphabet is planning to raise a substantial sum from stock sales, including private placements, convertible securitie...
AAPD’s 3.43% yield looks appealing, but the bear-on-Apple fund relies on collateral interest instead of dividends. A ...
A U.S.-listed ETF now prioritizes balance-sheet quality in developed markets, offering overseas exposure without weak...
Three ETFs are positioning investors for the next leg of AI-driven growth, offering diversified exposure as markets r...
Berkshire Hathaway is changing under Greg Abel, shifting toward concentrated bets on Apple and Alphabet. This article...
As the market keeps rates elevated, three dividend ETFs with over 6% yields offer straightforward income without upsi...
When rhythm pharma (rytm) releases earnings, investors get a window into revenue growth, cash health, and pipeline pr...